Established in 2009, Hubei Shengqi'an Biotechnology Co., Ltd. is a new biotechnology enterprise specializing in the research, development, application and promotion of drug-loaded vesicle treatment for cancer technology in China. It was officially listed in February 2017. The stock code: 870592. Sheng Qi'an Bio focuses on the field of cancer treatment, and has established products and research and development pipelines covering solid tumors and complications such as cholangiocarcinoma, lung cancer, malignant pleural effusion and malignant ascites. Up to now, drug-loaded vesicle treatment of tumor technology has been approved for marketing in Anhui, Shenzhen, Hubei and Tianjin provinces, and the first in the Department of Respiratory Medicine of the Second Affiliated Hospital of Anhui Medical University to carry out clinical application for the benefit of cancer patients. Based on the independent research and development of drug-loaded vesicles for the treatment of oncology technology, Sheng Qi'an Biotechnology has established a global patent system (Chinese Patent No.: ZL 201110241369.8) to establish the world's first drug-loaded vesicle treatment tumor technology.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Suzhou Sicui Institute of Immunology Technology Co., Ltd., established on 2021-09-17, Business scope includes general items:Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Technology promotion and application services;Information Technology Consulting Services;software development;Business Management Consulting;Entrepreneurial Space Services;Technology intermediary service;Intellectual Property Services(Except for patent agency services);Conference and Exhibition Services;business training(Does not include education and training,Vocational skills training and other licensed training);Educational Consulting Services(Education and training activities that do not include licensing approval);HR Services(Excludes job brokerage activities,Labor dispatch service);Office equipment rental service;Manufacturing of medical packaging materials;Pharmaceutical special equipment manufacturing;General equipment manufacturing(Does not include special equipment manufacturing);Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals);software sales;Experimental analysis instrument sales;Non-residential real estate leases;Import and export;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.